DK0554381T3 - Anvendelse af beskyttende midler mod reaktive oxygenforbindelser - Google Patents

Anvendelse af beskyttende midler mod reaktive oxygenforbindelser

Info

Publication number
DK0554381T3
DK0554381T3 DK91920537.7T DK91920537T DK0554381T3 DK 0554381 T3 DK0554381 T3 DK 0554381T3 DK 91920537 T DK91920537 T DK 91920537T DK 0554381 T3 DK0554381 T3 DK 0554381T3
Authority
DK
Denmark
Prior art keywords
reactive oxygen
protective agents
agents against
oxygen compounds
against reactive
Prior art date
Application number
DK91920537.7T
Other languages
Danish (da)
English (en)
Inventor
Grace H W Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24413043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0554381(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0554381T3 publication Critical patent/DK0554381T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/204IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
DK91920537.7T 1990-10-25 1991-10-21 Anvendelse af beskyttende midler mod reaktive oxygenforbindelser DK0554381T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60285090A 1990-10-25 1990-10-25

Publications (1)

Publication Number Publication Date
DK0554381T3 true DK0554381T3 (da) 1996-04-09

Family

ID=24413043

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91920537.7T DK0554381T3 (da) 1990-10-25 1991-10-21 Anvendelse af beskyttende midler mod reaktive oxygenforbindelser

Country Status (9)

Country Link
EP (1) EP0554381B2 (el)
JP (2) JPH06503320A (el)
AT (1) ATE133073T1 (el)
CA (1) CA2092718C (el)
DE (1) DE69116565T2 (el)
DK (1) DK0554381T3 (el)
ES (1) ES2084190T3 (el)
GR (1) GR3019229T3 (el)
WO (1) WO1992007578A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69423806T2 (de) * 1993-01-22 2000-08-17 Kanegafuchi Chemical Ind Therapeutisches Agens für NIDDM
US5661122A (en) * 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
US5935924A (en) * 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
AUPO263696A0 (en) * 1996-09-27 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A process for culturing cells
SE9703929D0 (sv) * 1996-11-22 1997-10-28 Pharmacia & Upjohn Ab Therapeutical use and method
EP1043027A1 (en) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
SI1471974T1 (sl) 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
WO2004014412A1 (ja) * 2002-08-09 2004-02-19 Kaken Pharmaceutical Co., Ltd. 心筋細胞保護剤
MXPA05003869A (es) * 2002-10-08 2005-06-22 Ares Trading Sa El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
KR20090107088A (ko) 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof

Also Published As

Publication number Publication date
EP0554381B2 (en) 2000-04-26
ES2084190T3 (es) 1996-05-01
GR3019229T3 (en) 1996-06-30
ATE133073T1 (de) 1996-02-15
JPH06503320A (ja) 1994-04-14
CA2092718C (en) 2007-08-07
EP0554381A1 (en) 1993-08-11
EP0554381B1 (en) 1996-01-17
JP2002179590A (ja) 2002-06-26
AU8941291A (en) 1992-05-26
DE69116565D1 (de) 1996-02-29
DE69116565T2 (de) 1996-08-01
WO1992007578A1 (en) 1992-05-14
AU661463B2 (en) 1995-07-27
CA2092718A1 (en) 1992-04-26

Similar Documents

Publication Publication Date Title
DK0554381T3 (da) Anvendelse af beskyttende midler mod reaktive oxygenforbindelser
Redmond et al. Surgical anatomy of the human spleen
SE7806939L (sv) Retentionspreparat for tandproteser
Southwick et al. Recurrence at the suture line following resection for carcinoma of the colon: incidence following preventive measures
DE69839586D1 (de) Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung
DE69327544D1 (de) Mischungen zum schutz und regenierung von geweben
ES2136618T3 (es) Cicatrizacion de heridas.
DE69931159D1 (de) Antimikrobielle zusammensetzungen enthaltend taurolidin, zitronensäure und natriumzitrat
KR970705413A (ko) 암의 광역학요법용 새로운 로다민 유도체 및 백혈병의 시험관내 정화(novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias)
LTIP1705A (en) Method for protection of cultured plant, method for combating with pests and microbicidal material
DE69100364D1 (de) Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
NZ308391A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
ES2133289T3 (es) Aumento en los niveles de glutation con glutamina.
Oosterhof et al. In vivo effects of high energy shock waves on urological tumors: an evaluation of treatment modalities
Lamke The influence of different “skin grafts” on the evaporative water loss from burns
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
AU3324100A (en) Use of pirenoxine for the protection of corneal tissues in photokeratectomy
JPS5562004A (en) Control agent against plant viral disease
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
EA200000762A1 (ru) Способ для консервации органов или других тканей для трансплантации
MILLER et al. HEALING OF SECOND DEGREE BURNS: Comparison of Effects of Early Application of Horaografts and Coverage with Tape
Stanley et al. Whitehead's varnish and Jelonet--a better dressing for skin graft donor sites than Jelonet alone.
EP0169895A1 (en) PLANT MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SOME HEPATIC AND BILIARY CONDITIONS.
Rice et al. The role of triglyceride accumulation and of necrosis in the hemodynamic responses of the isolated perfused rat liver after administration of carbon tetrachloride